”
Purification of capsular polysaccharides from contaminant LPS
The biological and physico- chemical characteristics of meningococcus polysaccharide Group C prepared by two different methods of purification
”
Vaccines based on the mutant diphteria protein CRM197
Immunogenic correlation between cross-reacting material (CRM197) produced by a mutant of
C. diphtheriae and diphtheria toxoid
”
Determination of group-specific polysaccharides in multivalent vaccines
Immunoelectrophoretic characterization of the molecular weight polydispersion of polysaccharides in multivalent bacterial capsular polysaccharide vaccines
”
Development of glycoconjugate vaccines combining the first generation of reductive animation with ester-activated linkers
Immunochemistry of Meningococcal group B oligosaccharide-protein conjugates
”
Development of glycoconjugate vaccines combining the first generation of reductive animation with ester-activated linkers
Specific antibodies to diphteria toxin and type 6A Pneumococcal capsular polysaccharide induced by a model of semi-synthetic glycoconjugate antigen
”
Development of glycoconjugate vaccines combining the first generation of reductive animation with ester-activated linkers
A semi-synthetic glycoconjugate antigen prepared by chemical glycosylation of pertussis toxin by a meningococcal group C oligosaccharide hapten
”
Development of glycoconjugate vaccines with
built-in multiple specificities
A molecular model of artificial gycoprotein with predetermined multiple immunodeterminants for Gram-Positive and Gram-negative encapsulated bacteria
”
Development of glycoconjugate vaccines with
built-in multiple specificities
Artificial glycoproteins of predetermined multivalent antigenicity as a new generation of candidate vaccines to prevent infections from encapsulated bacteria
”
Development of glycoconjugate vaccines combining the second generation of reductive amination with ester-activated
Strategies for type-specific glycoconjugate vaccines of Streptococcus pneumoniae
Our technology is based on 30 years of experience
BiosYnth s.r.l. - P.IVA 00736000522 - Capitale Sociale: € 520.000 I.V.
Developed by
